Results 141 to 150 of about 44,548 (260)
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction Clinical benefit measures and surrogates for leukaemic transformation or overall survival are scarce in MF. Circulating myeloblast (CMB) counts have the biological plausibility to indicate disease evolution, but they are still determined by an outdated approach with microscopic examination and fixed cut‐offs.
Malak Tamer Abdelmaksoud +6 more
wiley +1 more source
The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies
MedComm – Oncology, Volume 5, Issue 2, June 2026.Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao +4 more
wiley +1 more source
Magnetic Resonance in Medicine, Volume 95, Issue 6, Page 3386-3395, June 2026.ABSTRACT Purpose To improve accuracy of apparent diffusion coefficient (ADC) measurement across different bone‐marrow (BM) sites for myelofibrosis (MF) patients. Methods Vendor‐provided ADC gradient nonlinearity correction (GNC) was implemented for 41 MF study subjects on a 3T clinical scanner.
Dariya Malyarenko +9 more
wiley +1 more source
Clinical Endocrinology, Volume 104, Issue 6, Page 670-681, June 2026.ABSTRACT Objective Differentiated thyroid carcinoma (DTC) has an excellent prognosis, but recurrence remains a clinical concern, especially in intermediate‐risk patients. Current stratification systems focus primarily on tumor characteristics, overlooking the host's biological capacity to counteract tumor progression.
Tommaso Piticchio +11 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success ...
Keiko Yamamoto, Aya Iwase, Hideki Maeda
wiley +1 more source
A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib
Echocardiography, Volume 43, Issue 6, June 2026.In a retrospective cohort of 199 adult patients with CML on Dasatinib in a single quaternary center, approximately 25% patients had routine baseline and follow‐up echocardiogram. Dasatinib was associated with significant changes in structural and diastolic parameters.
Chen Chen +4 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 6, Page 850-862, June 2026.ABSTRACT Background Individuals with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) face transformation risks to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). While older age is linked to increased risk, it remains unclear whether risk increases with age or with disease duration.
Nurgul Batyrbekova +5 more
wiley +1 more source
International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 512-520, June 2026.ABSTRACT The recent fifth edition WHO classification and ICC classification systems have moved further toward genetically defined classifications of acute leukemias. Both now recognize myelodysplasia‐related (MR) mutations as defining of MDS‐related AML (AML‐MR).
Timothy J. Kirtek, Olga K. Weinberg
wiley +1 more source
Digital Pathology in Hematopathology: From Vision to Deployment
International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 531-540, June 2026.ABSTRACT Digital pathology (DP) has evolved alongside other technical advances, transforming our daily lives and diagnostic medicine. It is likely that, as in other areas of life, science, and medicine, the overall level of digitization will continue to rise, along with an increasing number of groups implementing DP.
Ryan C. Shean, Anton V. Rets
wiley +1 more source
Diagnosing Systemic Mastocytosis: State of the Art
International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 551-560, June 2026.ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley +1 more source